Division of Cardiology, Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, Atlanta, GA.
Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA.
J Am Heart Assoc. 2018 Feb 21;7(5):e007914. doi: 10.1161/JAHA.117.007914.
The associations between high-sensitivity troponin I (hsTnI) levels and coronary artery disease (CAD) severity and progression remain unclear. We investigated whether there is an association between hsTnI and angiographic severity and progression of CAD and whether the predictive value of hsTnI level for incident cardiovascular outcomes is independent of CAD severity.
In 3087 patients (aged 63±12 years, 64% men) undergoing cardiac catheterization without evidence of acute myocardial infarction, the severity of CAD was calculated by the number of major coronary arteries with ≥50% stenosis and the Gensini score. CAD progression was assessed in a subset of 717 patients who had undergone ≥2 coronary angiograms >3 months before enrollment. Patients were followed up for incident all-cause mortality and incident cardiovascular events. Of the total population, 11% had normal angiograms, 23% had nonobstructive CAD, 20% had 1-vessel CAD, 20% had 2-vessel CAD, and 26% had 3-vessel CAD. After adjusting for age, sex, race, body mass index, smoking, hypertension, diabetes mellitus history, and renal function, hsTnI levels were independently associated with the severity of CAD measured by the Gensini score (log 2 ß=0.31; 95% confidence interval, 0.18-0.44; <0.001) and with CAD progression (log 2 ß=0.36; 95% confidence interval, 0.14-0.58; =0.001). hsTnI level was also a significant predictor of incident death, cardiovascular death, myocardial infarction, revascularization, and cardiac hospitalizations, independent of the aforementioned covariates and CAD severity.
Higher hsTnI levels are associated with the underlying burden of coronary atherosclerosis, more rapid progression of CAD, and higher risk of all-cause mortality and incident cardiovascular events. Whether more aggressive treatment aimed at reducing hsTnI levels can modulate disease progression requires further investigation.
高敏肌钙蛋白 I(hsTnI)水平与冠状动脉疾病(CAD)严重程度和进展之间的关系仍不清楚。我们研究了 hsTnI 与 CAD 的严重程度和进展之间是否存在关联,以及 hsTnI 水平对心血管事件发生的预测价值是否独立于 CAD 严重程度。
在 3087 名年龄为 63±12 岁(64%为男性)、无急性心肌梗死证据的接受心脏导管检查的患者中,通过有≥50%狭窄的主要冠状动脉数量和 Gensini 评分来计算 CAD 的严重程度。在一个亚组中(717 名患者),在登记前至少进行了两次间隔 3 个月以上的冠状动脉造影检查,评估 CAD 的进展情况。对所有患者进行了全因死亡率和心血管事件发生的随访。在总人群中,11%的患者冠状动脉正常,23%的患者患有非阻塞性 CAD,20%的患者患有 1 支血管 CAD,20%的患者患有 2 支血管 CAD,26%的患者患有 3 支血管 CAD。在调整年龄、性别、种族、体重指数、吸烟、高血压、糖尿病史和肾功能后,hsTnI 水平与 Gensini 评分(log 2 ß=0.31;95%置信区间,0.18-0.44;<0.001)和 CAD 进展(log 2 ß=0.36;95%置信区间,0.14-0.58;=0.001)独立相关。hsTnI 水平也是全因死亡、心血管死亡、心肌梗死、血运重建和心脏住院的独立预测因子,独立于上述协变量和 CAD 严重程度。
较高的 hsTnI 水平与冠状动脉粥样硬化的潜在负担、CAD 更快的进展以及全因死亡率和心血管事件发生的风险增加相关。是否更积极地治疗以降低 hsTnI 水平可以调节疾病进展,这需要进一步的研究。